NP prescribing of molupiravir (Lageviro®) on the PBS
Update from the Pharmaceutical Benefits Advisory Committee
At its March 2022 meeting, the Pharmaceutical Benefits Advisory Committee (PBAC) considered the ACNP’s request to amend the PBS listing of molnupiravir to allow prescribing by nurse practitioners.
The PBAC recommended amending the current PBS listing for molnupiravir for treatment of SARS-CoV-2 infection to allow nurse practitioners to prescribe as a PBS benefit and to verify the rapid antigen test where required for eligibility.
The PBAC noted that amending the listing would align the PBS listing with nurse practitioner prescribing arrangements in some jurisdictions where they are able to prescribe molnupiravir through the National Medicines Stockpile.
This outcome and other outcomes of the March 2022 PBAC meeting were published on the PBS website on the 22nd April https://www.pbs.gov.au/info/news/2022/04/recommendations-made-by-the-pbac-march-2022
You may be also aware that the PBS listing of nirmatrelvir and ritonavir (Paxlovid®) was recommended by the PBAC and will be listed on the PBS commencing 1 May 2022. The PBAC advised that this product was suitable for prescribing by nurse practitioners.
We will have an update for members in the May edition In Focus, including the implementation date for this change. ACNP is very pleased to have had such a positive and swift response from PBAC in relation to treatment for SARS-CoV-2 infections, allowing for patients of nurse practitioners to have equitable access to care and affordable medicines.